Clinical pharmacokinetics of antibacterial drugs in the elderly. Implications for selection and dosage
- PMID: 2689039
- DOI: 10.2165/00003088-198917060-00003
Clinical pharmacokinetics of antibacterial drugs in the elderly. Implications for selection and dosage
Abstract
A review of the clinical pharmacokinetics of antibiotics in the healthy elderly reveals that for most compounds a decrease occurs in renal clearance (associated with age-related decreases in renal function), as well as a prolonged half-life and increased area under the plasma concentration-time curve. These changes are amplified in the sick infected elderly. It is important that the treating physician be aware of the potential side-effects of antimicrobial agents, and whenever possible choose those which are associated with the least adverse effects. Individual patient variability, including underlying diseases and other prescribed medications, must be taken into account when dosage is selected. beta-Lactam compounds have a remarkable safety record: specifically in the elderly, their therapeutic/toxic ratio is much higher than that observed with aminoglycosides. Regimens for this class of drugs in the elderly should maintain antibiotic concentrations above the minimum inhibitory concentrations for maximum efficacy. In the treatment of elderly patients, it is suggested that dosage and interval be based on estimated or measured creatinine clearance. Usually, for drugs that are excreted primarily by the kidney (i.e. amino-glycosides, beta-lactams and quinolones), dosage intervals must be increased when there is an associated fall in creatinine clearance. The pharmacokinetic parameters suggest that as an alternative to increasing dosage interval the usual dose may be decreased, but further studies are necessary for confirmation.
Similar articles
-
Quinolones in the aged.Drugs. 1999;58 Suppl 2:49-51. doi: 10.2165/00003495-199958002-00009. Drugs. 1999. PMID: 10553705 Review.
-
Use of aminoglycosides in elderly patients. Pharmacokinetic and clinical considerations.Drugs Aging. 1997 Apr;10(4):259-77. doi: 10.2165/00002512-199710040-00003. Drugs Aging. 1997. PMID: 9108987 Review.
-
The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents.Clin Pharmacokinet. 1995 Feb;28(2):143-60. doi: 10.2165/00003088-199528020-00005. Clin Pharmacokinet. 1995. PMID: 7736689 Review.
-
Pharmacokinetics and therapeutic drug monitoring of gentamicin in the elderly.Clin Pharmacokinet. 1999 Oct;37(4):331-41. doi: 10.2165/00003088-199937040-00004. Clin Pharmacokinet. 1999. PMID: 10554048 Review.
-
Optimisation of antibiotic therapy in cystic fibrosis patients. Pharmacokinetic considerations.Clin Pharmacokinet. 1993 Jun;24(6):496-506. doi: 10.2165/00003088-199324060-00005. Clin Pharmacokinet. 1993. PMID: 8513651 Review.
Cited by
-
Single-dose pharmacokinetics of oral fleroxacin in bacteremic patients.Antimicrob Agents Chemother. 1994 Jun;38(6):1219-24. doi: 10.1128/AAC.38.6.1219. Antimicrob Agents Chemother. 1994. PMID: 8092817 Free PMC article.
-
Effects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjects.Antimicrob Agents Chemother. 2005 Apr;49(4):1656-9. doi: 10.1128/AAC.49.4.1656-1659.2005. Antimicrob Agents Chemother. 2005. PMID: 15793165 Free PMC article.
-
Pharmacokinetics and safety of a new parenteral carbapenem antibiotic, biapenem (L-627), in elderly subjects.Antimicrob Agents Chemother. 1998 Jun;42(6):1433-6. doi: 10.1128/AAC.42.6.1433. Antimicrob Agents Chemother. 1998. PMID: 9624490 Free PMC article.
-
Aging exacerbates mortality of Acinetobacter baumannii pneumonia and reduces the efficacies of antibiotics and vaccine.Aging (Albany NY). 2018 Jul 18;10(7):1597-1608. doi: 10.18632/aging.101495. Aging (Albany NY). 2018. PMID: 30018181 Free PMC article.
-
Quinolones in the aged.Drugs. 1999;58 Suppl 2:49-51. doi: 10.2165/00003495-199958002-00009. Drugs. 1999. PMID: 10553705 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical